ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 661,65
-0,44%
Dow Jones
39 210,51
-0,25%
DAX
18 461,83
0,05%
Brent Oil
87,16
-0,19%
Bitcoin
55 382,13
-2,80%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Centogene NV (CNTG)

  7. Centogene NV (CNTG) Actualités

CNTG

Centogene NV (CNTG)

Centogene NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CNTG
DateHeureSourceTitreSymboleSociété
20/06/202414h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
20/06/202414h00GlobeNewswire Inc.C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug DevelopmentNASDAQ:CNTGCentogene NV
31/05/202422h30GlobeNewswire Inc.CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General MeetingNASDAQ:CNTGCentogene NV
17/05/202413h20Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:CNTGCentogene NV
15/05/202423h17GlobeNewswire Inc.CENTOGENE Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:CNTGCentogene NV
15/05/202423h12Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:CNTGCentogene NV
15/05/202423h10GlobeNewswire Inc.CENTOGENE Secures Approx. $20 Million to Strengthen Cash PositionNASDAQ:CNTGCentogene NV
14/05/202414h30GlobeNewswire Inc.CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher DiseaseNASDAQ:CNTGCentogene NV
10/05/202412h30GlobeNewswire Inc.CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsNASDAQ:CNTGCentogene NV
02/04/202422h30GlobeNewswire Inc.CENTOGENE Receives Nasdaq Non-Compliance NoticeNASDAQ:CNTGCentogene NV
19/03/202411h30GlobeNewswire Inc.CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersNASDAQ:CNTGCentogene NV
29/02/202423h00GlobeNewswire Inc.CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα DeficiencyNASDAQ:CNTGCentogene NV
28/02/202412h30GlobeNewswire Inc.CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingNASDAQ:CNTGCentogene NV
28/02/202412h30GlobeNewswire Inc.CENTOGENE Explores Strategic AlternativesNASDAQ:CNTGCentogene NV
25/01/202412h30GlobeNewswire Inc.CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationNASDAQ:CNTGCentogene NV
24/01/202412h30GlobeNewswire Inc.CENTOGENE Receives French Research Tax Credit AccreditationNASDAQ:CNTGCentogene NV
23/01/202412h30GlobeNewswire Inc.CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using MultiomicsNASDAQ:CNTGCentogene NV
18/01/202412h30GlobeNewswire Inc.CENTOGENE Announces Preliminary Full Year 2023 RevenueNASDAQ:CNTGCentogene NV
19/12/202312h30GlobeNewswire Inc.CENTOGENE Announces Voting Results of Extraordinary General MeetingNASDAQ:CNTGCentogene NV
13/12/202312h30GlobeNewswire Inc.CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneNASDAQ:CNTGCentogene NV
28/11/202312h30GlobeNewswire Inc.CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionNASDAQ:CNTGCentogene NV
14/11/202314h30GlobeNewswire Inc.CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and ParkinsonismNASDAQ:CNTGCentogene NV
10/10/202312h30GlobeNewswire Inc.CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic OfferingNASDAQ:CNTGCentogene NV
11/09/202314h30GlobeNewswire Inc.CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CNTGCentogene NV
07/09/202323h00GlobeNewswire Inc.CENTOGENE Reports First Half 2023 Financial ResultsNASDAQ:CNTGCentogene NV
01/09/202314h00GlobeNewswire Inc.CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease PatientsNASDAQ:CNTGCentogene NV
31/08/202322h30GlobeNewswire Inc.CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyNASDAQ:CNTGCentogene NV
07/08/202312h30GlobeNewswire Inc.CENTOGENE to Participate in Upcoming Conferences in AugustNASDAQ:CNTGCentogene NV
14/07/202312h30GlobeNewswire Inc.CENTOGENE Regains Compliance With Nasdaq Listing RequirementsNASDAQ:CNTGCentogene NV
12/07/202313h30GlobeNewswire Inc.CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease CohortNASDAQ:CNTGCentogene NV
 Showing the most relevant articles for your search:NASDAQ:CNTG

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
NASDAQ
MSFT
Microsoft
EU
BN
Danone
EU
LR
Legrand
EU
SGO
Cie de SaintGobain
EU
BEL20
Bel 20
EU
AI
Air Liquide
NYSE
NKE
Nike
EU
EN
Bouygues
NYSE
DIS
Walt Disney
COIN
ETHUSD
Ethereum
EU
ML
Michelin
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés